Sichuan Huiyu Pharmaceutical Co., Ltd

Established in 2010, Huiyu Pharmaceutical is a comprehensive pharmaceutical enterprise driven by research and development, mainly engaged in the research and development, production, and sales of anti-tumor and injection drugs. The company's headquarters and production base are located in the National Economic and Technological Development Zone of Neijiang City. The research and development center is located in Tianfu International Biological City, Chengdu, and has subsidiaries in the United States, the United Kingdom, and Ireland. The R&D team of the company is centered around experienced overseas returnee doctors, with over 600 R&D personnel, accounting for over 40% of the total number of the company. They have rich R&D experience in chemical raw materials, chemical ordinary injections, and complex injections. At the same time, they actively promote the research and development of small molecule innovative drugs and biopolymer innovative drugs in the anti-tumor field. The company has 109 ongoing research projects, including 12 Class I innovative drugs and 2 improved new drug projects, The pipeline mainly focuses on tumors and related fields, while gradually covering other fields. Overseas, Huiyu Pharmaceutical passed the UK GMP certification for the first time in 2014, and its wholly-owned subsidiary, Haiyue Pharmaceutical, passed the EU drug release qualification certification in July 2015. In the same year, its independent brand of anti-tumor injections achieved large-scale sales in the EU. The company owns or authorizes its partners to hold over 300 overseas approvals, and has signed cooperation agreements in nearly 100 countries, covering 6 continents. At present, Huiyu has 16 first-line anti-tumor injections and 2 other field formulations approved for marketing in the UK, and has been listed and sold in over 1000 medical institutions overseas. In China, in 2017, Pemetrexed disodium for injection passed consistency evaluation for the first time among the same variety. The following year, it won the bid for national centralized procurement and began large-scale sales in China, covering over 2000 grade hospitals. On October 26, 2021, it officially landed on the Science and Technology Innovation Board and became an innovative pharmaceutical enterprise with an international perspective. At present, the company has 13 drugs approved for marketing, including pemetrexed disodium for injection, docetaxel injection, azacytidine for injection, paclitaxel injection, oxaliplatin injection, bendamustine hydrochloride for injection, irinotecan injection, bortezomib for injection, palonosetron hydrochloride injection, plerixafor injection, and epirubicin hydrochloride for injection, And many of the varieties have been evaluated by the first or top three.